Remedium Bio
CompanyUnited States
Remedium Bio develops 3 assets, the furthest preclinical (AAV2-FGF18 in osteoarthritis). Mostly gene therapy acting on FGF18 and GLP1R; based in the United States.
- 3
- Assets
- Furthest stage
- Preclinical
- Raised
- US$13.8m
- 0
- Trials
- 1
- Signal
Pipeline
3Delivers FGF18 using an adeno-associated virus to promote cartilage anabolism.
Preclinical, Gene therapy, FGF18, osteoarthritis
Enables continuous subcutaneous production of a GLP-1 receptor agonist.
Preclinical, Gene therapy, GLP1R, obesity, type 2 diabetes
Promotes neuroprotection and neuro-regeneration in cerebral ischemia.
Preclinical, ischemic stroke
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Funding rounds and grants3
- People13
- Signals2
- Similar companies6